Myeloma Clinical Trials in San Francisco, California
17 recruitingSan Francisco, California
Showing 1–17 of 17 trials
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC157 enrolled31 locationsNCT07266441
Recruiting
Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Multiple Myeloma
Janssen Research & Development, LLC295 enrolled50 locationsNCT05201781
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting
Phase 1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Multiple Myeloma
Poseida Therapeutics, Inc.275 enrolled23 locationsNCT04960579
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RISS Stage I Plasma Cell MyelomaRISS Stage II Plasma Cell MyelomaPlasma Cell Myeloma
ECOG-ACRIN Cancer Research Group1,450 enrolled600 locationsNCT04566328
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
Kite, A Gilead Company450 enrolled124 locationsNCT06413498
Recruiting
Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company187 enrolled19 locationsNCT06153251
Recruiting
Phase 1
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Alfred Chung, MD32 enrolled1 locationNCT06348108
Recruiting
Phase 1
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRecurrent Multiple Myeloma
Thomas Martin, MD30 enrolled1 locationNCT07340853
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Multiple MyelomaMyeloma
K36 Therapeutics, Inc.125 enrolled22 locationsNCT05651932
Recruiting
Phase 1
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Tufts Medical Center400 enrolled13 locationsNCT06365060